[How to assess disease severity in chronic hepatitis B using non invasive fibrosis markers?]

2007 Hépato-Gastro & Oncologie Digestive 14, numéro spécial (23-28)

Assessment of disease severity is of critical importance in chronic hepatitis B not only for prognosis but also for treatment indication. Significant progress has been made in the non invasive diagnosis of hepatic fibrosis. Although an increasing number of markers are available, very few have been validated in chronic hepatitis B so far. Thus, liver biopsy should still be performed before starting antiviral therapy. Non invasive markers, particularly Fibroscan, could be useful for the follow-up of patients after initial liver biopsy and for the management of inactive carriers. It can be anticipated that with improvement of their diagnostic performance, non invasive markers will be increasingly used in the next future.

Pubmed : hpg.2007.0141